Referring physicians completed questionnaires on the effects of PET results on management decisions, and clinical follow-up was used to assess the relevance of decision changes to general outcomes and progression. ^sup 18^F-DOPA PET changed management in 18 of 71 (25%) patients whose physicians responded to the survey.
^sup 18^F-DOPA PET and Digestive Endocrine Tumors Anonymous The Journal of Nuclear Medicine; Mar 2009; 50, 3; Docstoc pg. 25N Reproduced with permission of the c
Pages to are hidden for
"^sup 18^F-DOPA PET and Digestive Endocrine Tumors"Please download to view full document